Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a study titled ...

Regeneron has demonstrated strong performance across crucial financial metrics, and we contend this is not fully captured in its current stock valuation, which renders it an attractive investment.

Recent Financial Performance. Regeneron has demonstrated strong financial performance, with a healthy gross profit margin of 50.75% and overall revenue growth of 5.72% over the last twelve months.

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 8.5% over the past three months. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s ...

This was the stock's second consecutive day of losses.

Most readers would already know that Regeneron Pharmaceuticals' (NASDAQ:REGN) stock increased by 9.6% over the past three months. Given that the market rewards strong financials in the long-term ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years.

While Regeneron stock has rallied by about 45% year-to-date, it still appears reasonably valued, ... What Has Driven Regeneron’s Performance In Recent Years?

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 1.4% over the past week. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s ...